おすすめの製品
グレード
pharmaceutical primary standard
APIファミリー
diacerein
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O
InChI
1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)
InChI Key
TYNLGDBUJLVSMA-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
関連するカテゴリー
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Diacerein EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
ターゲットの組織
Respiratory system
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
最新バージョンのいずれかを選択してください：
D Provvedini et al.
Presse medicale (Paris, France : 1983), 31(39 Pt 2), 4S13-4S15 (2003-01-09)
SYMPTOMATIC EFFECTS OF DIACEREIN: Data obtained from several clinical trials have demonstrated that relief of joint pain obtained with the interleukin-1 inhibitor diacerein is comparable with that observed with non-steroidal anti-inflammatory drugs (NSAIDS) after four to six weeks of treatment
G Falgarone et al.
Current rheumatology reports, 3(6), 479-483 (2001-11-16)
This paper reviews the most recent clinical and experimental studies on diacerein, both of which are under investigation. Diacerein could be a disease-modulating agent in osteoarthritis because structural benefits have been reported in recent trials. Moreover, after an empirical use
P Nicolas et al.
Clinical pharmacokinetics, 35(5), 347-359 (1998-12-05)
Diacerein is a drug for the treatment of patients with osteoarthritis. This drug is administered orally as 50 mg twice daily. Diacerein is entirely converted into rhein before reaching the systemic circulation. Rhein itself is either eliminated by the renal
T S A Fidelix et al.
The Cochrane database of systematic reviews, (1)(1), CD005117-CD005117 (2006-01-27)
Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases. Diacerein acts differently from traditional non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit prostaglandin synthesis, leading to adverse gastrointestinal effects. It has been proposed that diacerein acts as a slow-acting, symptom-modifying and
[Diacerein].
G Passiu
Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna, 1(2), 172-174 (1986-06-01)
アクティブなフィルタ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）
